E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019

Publisher Name :
Date: 10-Jun-2019
No. of pages: 86

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019

Summary

According to the recently published report 'E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019'; E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - E3 Ubiquitin-Protein Ligase X-linked inhibitor of apoptosis protein (XIAP) also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4) is a protein that stops apoptotic cell death. It modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. It acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. It inactivates CASP9 by keeping it in inactive state. It regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. It acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs).

The report 'E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019' outlays comprehensive information on the E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 4 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Breast Cancer, Cervical Cancer, Colorectal Cancer, Head And Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma and Relapsed Multiple Myeloma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)

- The report reviews E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

- The report assesses E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Overview
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Companies Involved in Therapeutics Development
Adamed Sp zoo
Astex Pharmaceuticals Inc
Canget BioTekpharma LLC
Novartis AG
Noxopharm Ltd
Takeda Pharmaceutical Co Ltd
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Drug Profiles
ADO-532 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTX-660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FL-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idronoxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit XIAP for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit XIAP for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3256336 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Dormant Products
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Discontinued Products
E3 Ubiquitin Protein Ligase XIAP (Baculoviral IAP Repeat Containing Protein 4 or IAP Like Protein or Inhibitor Of Apoptosis Protein 3 or X Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Product Development Milestones
Featured News & Press Releases
May 30, 2019: Noxopharm announces its DARRT-1 study fully enrolled
May 21, 2019: Debiopharm expands its immuno-oncology development program for Debio 1143, with the first IAP inhibitor/Nivolumab combination trial
May 20, 2019: LuPIN trial demonstrates high rates of response
May 02, 2019: DARRT treatment has lasting disease control at six months
Apr 16, 2019: Idronoxil confirmed as new immuno-oncology drug
Apr 10, 2019: Veyonda chemotherapy
Apr 01, 2019: Debiopharm releases results of its oncology drug candidate Debio 1143 at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA
Feb 21, 2019: Noxopharm to expedite Veyonda clinical program
Feb 06, 2019: Combination of Veyonda + Radiotherapy delivers clinical benefits
Jan 14, 2019: Noxopharm: Principal Investigator discusses LuPIN-1 Study
Dec 20, 2018: NOX Receives $3.26M Federal Govt R&D Rebate
Dec 11, 2018: Darrt-1 study advancing on basis of positive clinical data
Nov 29, 2018: NOX announces positive data from CEP-1 study of Veyonda
Nov 13, 2018: NOX to present clinical data at COSA Annual Meeting
Oct 22, 2018: Noxopharm makes key executive appointment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Adamed Sp zoo, H1 2019
Pipeline by Astex Pharmaceuticals Inc, H1 2019
Pipeline by Canget BioTekpharma LLC, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Noxopharm Ltd, H1 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
  • Global Garlic Extract Market Insights, Forecast to 2025
    Published: 17-Jul-2019        Price: US 3900 Onwards        Pages: 115
    The substitute use of the garlic is made by the garlic extract which has no odor and has high antioxidant properties. The garlic extracts have several health benefits, thus is consumed widely. The garlic extract finds its application in the food, pharmaceutical, and personal care industries. The global Garlic Extract market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to de......
  • Global Parasitic Diseases Therapeutic Market Size, Status and Forecast 2019-2025
    Published: 17-Jul-2019        Price: US 3900 Onwards        Pages: 95
    Parasitic diseases include amebiasis, trichomoniasis, trypanosomiasis, giardiasis, African sleeping sickness, leishmaniasis, and malaria. In 2018, the global Parasitic Diseases Therapeutic market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Parasitic Diseases Therapeutic status, future forecast, growth opportunity, key market and key players. The study objectives......
  • Global Cancer Supportive Care Drugs Market Size, Status and Forecast 2019-2025
    Published: 17-Jul-2019        Price: US 3900 Onwards        Pages: 95
    Supportive drugs are not anticancer drugs. They protect certain cells or organs from the side effects of chemotherapy drugs or radiation therapy. Increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments are anticipated to drive the growth. In 2018, the global Cancer Supportive Care Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of......
  • Global Thyroid Disorder Market Size, Status and Forecast 2019-2025
    Published: 17-Jul-2019        Price: US 3900 Onwards        Pages: 93
    Thyroid disorders may lead to elevated or decreased levels of metabolic hormones, leading to medical conditions such as hypothyroidism, hyperthyroidism, etc. falling under the category of thyroid disorders. The global thyroid disorder market is estimated to be driven by the increasing prevalence of thyroid diseases, raising awareness of the disease, and favorable reimbursement and funding policies. According to the Thyroid Disease: Assessment and Management Draft of the National Institute for He......
  • Global Children Cough Medicine Market Size, Status and Forecast 2019-2025
    Published: 17-Jul-2019        Price: US 3900 Onwards        Pages: 91
    A cough is a sudden, and often repetitively occurring, protective reflex which helps to clear the large breathing passages from fluids, irritants, foreign particles and microbes. Children Cough Medicine helps control your child's cough plus thins and loosens mucus to relieve chest congestion so your child can get back to normal. In 2018, the global Children Cough Medicine market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% durin......
  • Global Nano Antibodies Market Size, Status and Forecast 2019-2025
    Published: 17-Jul-2019        Price: US 3900 Onwards        Pages: 90
    Nanoantibodies or "nAb" are single-domain VHH antibodies derived from camelidae (camels, llamas, alpacas, etc.). Compared with conventional monoclonal and polyclonal antibodies, nAbs have the following advantages: Small size (~15kd) High affinity (frequently nanomolar range) High specificity Unsurpassed stability In 2018, the global Nano Antibodies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx......
  • Global 7-Aminocephalosporanic Acid (7-ACA) Market Professional Survey 2019 by Manufacturers, Regions, Countries, Types and Applications, Forecast to 2024
    Published: 17-Jul-2019        Price: US 2900 Onwards        Pages: 194
    The 7-Aminocephalosporanic Acid (7-ACA) market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for 7-Aminocephalosporanic Acid (7-ACA). Global 7-Aminocephalosporanic Acid (7-ACA) industry market professional research 2014-2024, is a report which provides the details about ind......
  • Global (United States, European Union and China) Acral Lentiginous Melanoma Treatment Market Research Report 2019-2025
    Published: 17-Jul-2019        Price: US 3280 Onwards        Pages: 110
    Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. In 2019, the market size of Acral Lentiginous Melanoma Treatment is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast pe......
  • Global (United States, European Union and China) Sunitinib Malate Market Research Report 2019-2025
    Published: 17-Jul-2019        Price: US 3280 Onwards        Pages: 110
    The demand of sunitinib malate is increasing, and global advancement of technology and increasing prevalence of pancreatic cancer are the prime growth drivers of the global sunitinib malate market. In 2019, the market size of Sunitinib Malate is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs